Submission of Matters to a Vote of Security Holders
Show detailsHide details
5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Anaptysbio, Inc.
A biotechnology company built around a platform that mimics somatic hypermutation — the natural process the human immune system uses to mature antibodies against threats. Founded in 2005 in San Diego by antibody engineers Tillman Gerngross and Nicholas Lydon, it developed drugs including dostarlimab (Jemperli), a cancer immunotherapy licensed to GSK. In 2026 it spun off its drug-development arm and now focuses on collecting royalties from its former programs. Its name nods to the antibody biology at its roots.
5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure
1.01 Entry into a Material Definitive Agreement
7.01 Regulation FD Disclosure
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
1.01 Entry into a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 8.01 Other Events · 9.01 Financial Statements and Exhibits